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Abstract
Summary We conducted a case–control study to examine
osteonecrosis (ON) incidence, patient characteristics, and
selected potential risk factors using two health record
databases in the UK. Statistically significant risk factors
for ON included systemic corticosteroid use, hospitali-
zation, referral or specialist visit, bone fracture, any
cancer, osteoporosis, connective tissue disease, and
osteoarthritis.
Introduction The purpose of this case–control study was to
examine the incidence of osteonecrosis (ON), patient
characteristics, and selected potential risk factors for ON
using two health record databases in the UK: the General
Practice Research Database and The Health Improvement
Network.
Methods ON cases (n=792) were identified from 1989 to
2003 and individually matched (age, sex, and medical
practice) up to six controls (n=4,660) with no record of
ON. Possible risk factors were considered for inclusion
based on a review of published literature. Annual incidence
rates were computed, and a multivariable logistic regression
model was derived to evaluate selected risk factors.
Results ON of the hip represented the majority of cases
(75.9%). Statistically significant risk factors for ON were
systemic corticosteroid use in the previous 2 years, hospi-
talization, referral or specialist visit, bone fracture, any
cancer, osteoporosis, connective tissue disease, and osteo-
arthritis within the past 5 years. Only 4.4% of ON cases
were exposed to bisphosphonates within the previous
2 years.
Conclusions This study provides further perspective on the
descriptive epidemiology of ON. Studies utilizing more
recent data may further elucidate the understanding of ON
key predictors.
Keywords Avascularnecrosis.Epidemiology.
Osteonecrosis.Riskfactors
Introduction
Osteonecrosis (ON), also known as avascular necrosis and
aseptic necrosis, is defined as bone cell death following a
compromise of blood flow to the bone. ON is most
common in the femoral head (i.e., hip) but can occur at
any skeletal site (e.g., knee, shoulder, and ankle) [1, 2]. The
majority of ON cases are secondary to trauma [1]. Non-
traumatic ON can also occur, but the underlying pathology
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Cincinnati, OH 45219, USAis unclear [1, 3]. In published literature, non-traumatic ON has
been associated with a number of risk factors including
corticosteroid use, alcohol consumption, immunosuppressive
therapy, autoimmune diseases such as systemic lupus eryth-
ematosus and rheumatoid arthritis, hematologic/thrombotic
disorders, malignancies and metabolic disorders such as
diabetes mellitus, and renal failure [1, 3–5]. Patients who
experience non-traumatic ON usually have more than one risk
factor, which indicates the pathogenesis of non-traumatic ON
is probably multifactorial [2].
The majority of studies to date have assessed risk factors for
ON in specific diseases with corticosteroid use, e.g., systemic
lupus erythematosus and organ transplantation [4–7]. Few
studies have been conducted in a general population [3, 8].
The purpose of this study was to examine the incidence of
ON, patient characteristics, and selected potential risk factors
for ON in two general population health record databases in
the UK: the General Practice Research Database (GPRD) and
The Health Improvement Network (THIN) database.
Methods
Study population and databases
The GPRD database contains computerized information
entered by approximately 450 general practitioners in the
UK. Data on approximately 3.4 million active patients (total
of approximately 13 million) are systematically recorded,
anonymized, and sent to GPRD where the data are collated
and organized for research purposes. Symptoms and
diagnoses are coded using the Oxford Medical Information
System (OXMIS) and the READ clinical classification
system. The THIN database contains similar information
entered by general practitioners in the UK and contains
information on over six million patients from 358 general
practice offices, including data on approximately 2.8 million
active patients.
Only data from medical practices that passed quality
control checks are included in the GPRD database [9]. Both
the GPRD and THIN databases have been validated in
several independent studies [10–14]. Both databases use the
READ classification to code specific diagnoses; a drug
dictionary based on the MULTILEX classification is used
to code drugs. Information collected in both of the
databases includes patient demographics and records of
primary care visits as well as diagnoses from specialist
referrals, hospital admissions, and the results of laboratory,
radiographic, and diagnostic tests. Prescriptions issued by
general practitioners are also recorded. Practices selected
from THIN did not contribute to the GPRD during the
study period, thereby avoiding duplication of ON cases.
Each database was screened for all permanently regis-
tered adults (aged 18 years or older) from 1989 to 2003.
ON was defined as a patient with a record of at least one of
the READ codes listed in Table 1. For each identified case,
the first record of ON during the period of data collection
was considered the index date. Within each database, each
case was matched to up to six controls with no record of
ON. The matching criteria included age (± 5 years), sex,
and medical practice (registered at the same practice at the
index date of the case). The index date of each control
patient was assigned the same date as the corresponding
matched case. Cases and controls were required to have a
READ/OXMIS code Description
7201NB Necrosis bone
7239AF Femur head avascular necrosis
7239AH Hip avascular necrosis
9906ON Osteoradio necrosis
N334000 Avascular necrosis of bone, site unspecified
N334100 Avascular necrosis of the head of humerus
N334200 Avascular necrosis of the head of femur
N334300 Avascular necrosis of the medial femoral condyle
N334311 Femoral condylar avascular necrosis
N334400 Avascular necrosis of the talus
N334500 Avascular necrosis of capitellum
N334600 Avascular necrosis of lateral femoral condyle
N334700 Avascular necrosis of other bone
N334800 Idiopathic aseptic necrosis of bone
N334900 Osteonecrosis due to drugs
N334A00 Osteonecrosis due to previous trauma
N334z00 Avascular bone necrosis NOS
Table 1 List of READ/OXMIS
codes used for identifying
osteonecrosis cases
NOS not otherwise specified
570 Osteoporos Int (2010) 21:569–577minimum of 3 months (i.e., 91 days) enrollment prior to the
index date.
The overall study design was a case–control study that
combined information from each of the two databases
(GPRD and THIN). Cases with a diagnosis of ON were
further assessed by examining the free text fields with key
search terms for each subject. After identifying all
diagnoses of ON, the incidence of ON was computed over
time, and analyses were carried out to explore potential risk
factors for ON.
Statistical methods and analysis
Incidences were calculated using midyear population
counts. Possible risk factors, selected a priori, were
considered for inclusion based on a review of the potential
risk factors previously cited in the published literature
[1, 4–7, 15]. Risk factors of interest included (1) drug
exposure (including systemic corticosteroids, immunosup-
pressants, anti-infectives, bisphosphonates, statins, and
hormone replacement therapy (HRT; women only)) in the
2 years prior to the index date and (2) medical history
(including hospitalization, referral or specialist visit, bone
fracture, any cancer including hematological cancer,
inflammatory bowel disease (IBD), gout, solid organ or
bone transplantation, asthma, renal failure or dialysis,
congenital or acquired hip dislocation, diabetes mellitus,
osteoporosis, connective tissue disease, and osteoarthritis)
in the 5 years prior to the index date. Each of these potential
risk factors was separately entered into a regression model.
Additionally, alcohol consumption was considered (depending
on the proportion of subjects with data for this variable).
Baseline demographic characteristics for cases and controls
were compared.
Crude odds ratios (ORs) and 95% confidence intervals
(CIs) were calculated for each risk factor in a univariate
analysis using conditional logistic regression, comparing
cases and controls. After excluding risk factors that had an
insignificant OR or did not reach an overall 1% prevalence,
a final, multivariable logistic regression model was derived.
Results
A total of 792 cases and 4,660 controls were included in the
analysis, with 99% of cases having at least five matched
controls. Fifty-three percent of the cases and 53.1% of the
controls were female, with a mean age of 57.5 years among
cases and 57.6 years among controls. Mean observation
time was 8.9 person-years for cases and 9.4 person-years
for controls. The most common site of ON was the hip,
representing 75.9% of the cases (Table 2).
The age-adjusted annual incidence rates of ON by sex
and the osteonecrosis incidence rates by sex and age
cohort are shown in Figs. 1 and 2. Overall, the recorded
incidence of ON increased over time from approximately
1.4/100,000 in 1989 to approximately 3/100,000 in 2003.
The incidence of ON in women was higher than men from
1989 to 1998; however, from 1999 through 2003, there
was a shift to men having a higher incidence than women
Cases (N=792) Controls (N=4,660) Overall (N=5,452)
Sex
Female 420 (53.0%) 2,473 (53.1%) 2,893 (53.1%)
Male 372 (47.0%) 2,187 (46.9%) 2,559 (46.9%)
Age (years)
Mean (SD) 57.5 (18.99) 57.6 (18.90) 57.6 (18.91)
Median (IQR) 58.5 (42.0–73.0) 59.0 (42.0–73.0) 59.0 (42.0–73.0)
Person-years of observation
Mean (SD) 8.9 (4.1) 9.4 (4.0) 9.4 (4.0)
Median (IQR) 9.3 (5.9–11.8) 9.7 (6.3–12.5) 9.7 (6.2–12.5)
Site of osteonecrosis
Hip 601 (75.9%) 0 (0.0%) 601 (11.0%)
Wrist 36 (4.5%) 0 (0.0%) 36 (0.7%)
Knee 20 (2.5%) 0 (0.0%) 20 (0.4%)
Shoulder 18 (2.3%) 0 (0.0%) 18 (0.3%)
Foot 15 (1.9%) 0 (0.0%) 15 (0.3%)
Ankle 13 (1.7%) 0 (0.0%) 13 (0.2%)
Jaw 3 (0.4%) 0 (0.0%) 3 (0.1%)
Other
a 20 (2.5%) 0 (0.0%) 20 (0.4%)
NOS 66 (8.3%) 0 (0.0%) 66 (1.2%)
Table 2 Baseline characteristics
of cases and controls
aOther sites (≤5 cases each)
included head of humerus,
medial femoral condyle, talus,
femoral condylar, larynx, pelvis,
rib, temp bone, and tibia
SD standard deviation; IQR
interquartile range; NOS not
otherwise specified
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increased with age. The incidence of ON in men remained
constant from age 40 to 79 (around 2/100,000), increasing
to 3/100,000 at age 80 years and older. From ages 18–59,
men had a higher incidence than women; however, women
60 years and older had a higher incidence than men
(Fig. 2).
Table 3 shows descriptive statistics for each of the
potential risk factors of interest. Drug exposure was
captured over the prior 2-year period and classified a
priori, as follows: None; Exposed (2+ prescriptions
within 120 days in the previous 2 years); or Intermittent
(all other possible exposure scenarios). In the study
population, anti-infectives were the most commonly
prescribed therapy (22.9% among cases and 15.3%
among controls). Relevant medical history was captured
for the previous 5 years. The most commonly reported
disease condition was osteoarthritis in 21.7% of cases
and 7.8% of controls. A large proportion of subjects
were missing data for alcohol consumption (46.3% of
cases and 51.2% of controls; Table 3), and it was,
therefore, decided to exclude this variable from multivariable
modeling (Tables 4 and 5).
Statistically elevated crude ORs were observed for
bisphosphonates, systemic corticosteroids, immunosuppres-
sants (intermittent only), anti-infectives, and HRT (exposed
only; Table 4). Marked differences between cases and
controls were noted for hospitalization, referral or specialist
visit, and bone fracture in the prior 5-year period, and,
despite a relatively small proportion of exposed subjects,
the crude ORs were also significantly increased for cancer,
IBD, gout, solid organ or bone transplantation, asthma,
renal failure or dialysis, osteoporosis, connective tissue
disease, and osteoarthritis (Table 4). Statistically significant
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Fig. 1 Age-adjusted annual in-
cidence rates by sex (GPRD and
THIN research databases)
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Fig. 2 Osteonecrosis incidence
rates by sex and age cohort
(1989–2003). Incidence rates are
weighted average of the annual
sex- and age-cohort-specific in-
cidence rates (GPRD and THIN
research databases)
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Drug exposures of interest (within the past 2 years)
Bisphosphonates
None 757 (95.6%) 4,607 (98.9%) <.01
Intermittent 26 (3.3%) 31 (0.7%) <.01
Exposed 9 (1.1%) 22 (0.5%) .02
Systemic corticosteroids
None 648 (81.8%) 4,422 (94.9%) <.01
Intermittent 108 (13.6%) 187 (4.0%) <.01
Exposed 36 (4.5%) 51 (1.1%) <.01
Immunosuppressants
None 757 (95.6%) 4,643 (99.6%) <.01
Intermittent 32 (4.0%) 12 (0.3%) <.01
Exposed 3 (0.4%) 5 (0.1%) .07
Anti-infectives
None 372 (47.0%) 2,787 (59.8%) <.01
Intermittent 239 (30.2%) 1,162 (24.9%) <.01
Exposed 181 (22.9%) 711 (15.3%) <.01
Statins
None 780 (98.5%) 4,530 (97.2%) .04
Intermittent 11 (1.4%) 110 (2.4%) .09
Exposed 1 (0.1%) 20 (0.4%) .20
HRT (women only)
None 374 (89.0%) 2,285 (92.4%) .02
Intermittent 18 (4.3%) 88 (3.6%) .46
Exposed 28 (6.7%) 100 (4.0%) .02
Medical history in the 5 years prior
Hospitalization 267 (33.7%) 790 (17.0%) <.01
Referral or specialist visit 401 (50.6%) 1,563 (33.5%) <.01
Bone fracture 175 (22.1%) 213 (4.6%) <.01
Any cancer (includes hematological cancer) 31 (3.9%) 53 (1.1%) <.01
IBD 14 (1.8%) 12 (0.3%) <.01
Gout 17 (2.1%) 40 (0.9%) <.01
Solid organ or bone marrow transplantation 5 (0.6%) 2 (0.0%) <.01
Asthma 56 (7.1%) 202 (4.3%) <.01
Renal failure or dialysis 11 (1.4%) 4 (0.1%) <.01
Congenital or acquired hip dislocation 2 (0.3%) 2 (0.0%) .02
Diabetes mellitus 19 (2.4%) 135 (2.9%) .43
Osteoporosis 29 (3.7%) 44 (0.9%) <.01
Connective tissue disease 52 (6.6%) 68 (1.5%) <.01
Osteoarthritis 172 (21.7%) 363 (7.8%) <.01
Alcohol consumption
Missing 367 (46.3%) 2,387 (51.2%) .01
Non-drinker 69 (8.7%) 422 (9.1%) .75
Light drinker 251 (31.7%) 1,441 (30.9%) .67
Moderate drinker 78 (9.8%) 342 (7.3%) .01
Heavy/very heavy drinker 27 (3.4%) 68 (1.4%) .11
Table 3 Potential risk factors of
interest
IBD inflammatory bowel
disease; HRT hormone
replacement therapy
Exposed is defined as 2+ pre-
scriptions within 120 days in the
past 2 years; intermittent is
defined as all other exposure
scenarios
Osteoporos Int (2010) 21:569–577 573risk factors for ON from the final multivariable logistic
regression model were systemic corticosteroid use (inter-
mittent and exposed), hospitalization, referral or specialist
visit, bone fracture, any cancer, osteoporosis, connective
tissue disease, and osteoarthritis (Table 4).
An additional analysis was performed in the subset of
cases with hip ON and their matched controls because these
represented a potentially more homogeneous population
and also included the majority (75.9%) of the identified ON
cases overall (Table 2). A total of 601 cases and 3,533
controls were included in the hip ON subset analysis.
Approximately 54% of cases and controls in the hip ON
subset were female with a mean age of 58.3 years.
Statistically significant risk factors for hip ON from the
adjusted multivariable logistic regression model were the
same as the overall ON population except for the inclusion
Variable Crude OR (95% CI) Adjusted
a OR (95% CI)
Drug exposures of interest (within the past 2 years)
Bisphosphonates
Intermittent 5.5 (3.21, 9.53) 1.4 (0.68, 2.87)
Exposed 2.8 (1.26, 6.07) 1.1 (0.40, 3.03)
Systemic corticosteroids
Intermittent 4.1 (3.17, 5.27) 3 (2.15, 4.05)
Exposed 5.3 (3.42, 8.33) 3.4 (1.95, 5.82)
Immunosuppressants
Intermittent 15.6 (8.03, 30.30) –
b
Exposed 3.5 (0.84, 14.73) –
b
Anti-infectives
Intermittent 1.6 (1.36, 1.95) 1.2 (0.98, 1.47)
Exposed 2.1 (1.69, 2.57) 1.2 (0.95, 1.55)
Statins
Intermittent 0.6 (0.29, 1.05) –
b
Exposed 0.3 (0.04, 2.15) –
b
HRT (women only)
Intermittent 1.3 (0.78, 2.30) –
c
Exposed 1.9 (1.20, 3.12) –
c
Medical history in the 5 years prior
Hospitalization 3.4 (2.80, 4.19) 1.8 (1.41, 2.25)
Referral or specialist visit 3.6 (2.88, 4.44) 2.2 (1.74, 2.85)
Bone fracture 6.5 (5.13, 8.15) 5.8 (4.43, 7.49)
Any cancer, including hematological cancer 3.6 (2.29, 5.75) 3.5 (2.05, 5.82)
IBD 7.3 (3.30, 16.10) –
b
Gout 2.7 (1.49, 4.84) 1.9 (0.95, 3.63)
Solid organ or bone transplantation 15 (2.91, 77.31) –
b
Asthma 1.7 (1.26, 2.34) 0.9 (0.62, 1.33)
Renal failure or dialysis 16.5 (5.25, 51.81) –
b
Congenital or acquired hip dislocation 6 (0.85, 42.71) –
b
Diabetes mellitus 0.8 (0.51, 1.34) –
b
Osteoporosis 4.3 (2.60, 6.99) 2.1 (1.07, 4.23)
Connective tissue disease 4.9 (3.37, 7.14) 2.6 (1.65, 4.11)
Osteoarthritis 4.1 (3.26, 5.13) 4.1 (3.16, 5.28)
Alcohol consumption
Missing 0.9 (0.67, 1.21)
Light drinker 1.1 (0.81, 1.47)
Moderate drinker 1.5 (1.03, 2.17)
Heavy/very heavy drinker 2.6 (1.54, 4.46)
Table 4 Multivariable logistic
regression modeling: selected
potential risk factors of osteo-
necrosis at any site
OR odds ratio; IBD inflamma-
tory bowel disease; HRT
hormone replacement therapy;
Exposed 2+ prescriptions within
120 days in the past 2 years;
Intermittent all other exposure
scenarios
aThe final multivariable logistic
regression model was adjusted
for bisphosphonates, systemic
corticosteroids, anti-infectives,
hospitalization, referral or spe-
cialist visit, bone fracture, any
cancer, gout, asthma, osteoporo-
sis, connective tissue disease,
and osteoarthritis
bVariables excluded from the
final regression model based on
either not reaching 1% overall
prevalence or crude OR was not
statistically significant
cHRT was excluded from the
final regression model in order
to retain the full sample (men
and women)
574 Osteoporos Int (2010) 21:569–577of immunosuppressant use (intermittent) and the exclusion
of osteoporosis (Table 5).
Of recent interest is the use of bisphosphonates and a
postulated association with osteonecrosis of the jaw (ONJ)
[16–19]. In our case–control study, only 4.4% of ON cases
were bisphosphonate users within the previous 2 years
(Table 3). Across all cases, only three had the jaw
mentioned as the site of ON, and none of them had been
exposed to bisphosphonates (Table 2).
Table 6 reports the type of bisphosphonate exposure for
cases and controls in this study. Etidronate was the most
common compound reported; this was the only oral
bisphosphonate marketed for the treatment of osteoporosis
in the UK in the early 1990s. Further, the distribution by
type of bisphosphonate is overall consistent with market
share in the UK during the study period. No cases or
controls with intravenous bisphosphonate use were identi-
fied in this study. Exposure to bisphosphonates was not
Risk factor Crude OR (95% CI) Adjusted
a OR (95% CI)
Drug exposures of interest (within the past 2 years)
Bisphosphonates
Intermittent 6 (3.24, 11.15) 1.7 (0.37, 7.72)
Exposed 3.1 (1.17, 8.20) 0.7 (0.11, 4.25)
Systemic corticosteroids
Intermittent 4.2 (3.12, 5.58) 3.1 (1.93, 4.95)
Exposed 4.8 (2.84, 7.98) 3 (1.37, 6.44)
Immunosuppressants
Intermittent 22.4 (9.76, 51.54) 6 (1.94, 18.38)
Exposed 2.3 (0.45, 12.05) 1.1 (0.07, 16.52)
Anti-infectives
Intermittent 1.6 (1.26, 1.91) 1.1 (0.79, 1.40)
Exposed 1.7 (1.37, 2.22) 1.2 (0.82, 1.65)
Statins
Intermittent 0.7 (0.32, 1.36) –
b
Exposed 0 (0) –
b
HRT (women only)
Intermittent 1.1 (0.58, 2.27) –
c
Exposed 1.7 (0.97, 3.15) –
c
Medical history in the 5 years prior
Hospitalization 3.3 (2.61, 4.13) 2 (1.43, 2.80)
Referral or specialist visit 3.2 (2.53, 4.14) 2.1 (1.50, 3.07)
Bone fracture 6.5 (4.94, 8.47) 5.8 (3.96, 8.56)
Any cancer, including hematological cancer 3.2 (1.88, 5.55) 2.8 (1.20, 6.31)
IBD 10.5 (4.19, 26.50) –
b
Gout 2.8 (1.47, 5.41) 2.3 (0.85, 6.37)
Solid organ or bone transplantation 24 (2.68, 214.68) –
b
Asthma 1.8 (1.25, 2.57) 1 (0.55, 1.73)
Renal failure or dialysis 32.9 (7.31, 148.49) –
b
Congenital or acquired hip dislocation 6 (0.85, 42.71) –
b
Diabetes mellitus 0.8 (0.44, 1.36) –
b
Osteoporosis 3.9 (2.23, 6.98) 2.8 (0.93, 8.35)
Connective tissue disease 5.6 (3.69, 8.64) 2.5 (1.19, 5.39)
Osteoarthritis 4.3 (3.35, 5.53) 5 (3.51, 7.02)
Alcohol consumption
Missing 0.9 (0.67, 1.33)
Light drinker 1.1 (0.78, 1.54)
Moderate drinker 1.4 (0.94, 2.22)
Heavy/very heavy drinker 2.7 (1.47, 5.03)
Table 5 Multivariable logistic
regression modeling: selected
potential risk factors for
osteonecrosis of the hip (subset
N=4134)
N=601 cases and 3,533 controls
OR odds ratio; IBD inflammatory
bowel disease; HRT hormone
replacement therapy, Exposed
2+ prescriptions within 120 days
in the past 2 years; Intermittent
all other exposure scenarios
aThe final multivariable logistic
regression model was adjusted for
bisphosphonates,systemiccortico-
steroids, immunosuppressants,
anti-infectives, hospitalization,
referral or specialist visit, bone
fracture, any cancer, gout, asthma,
osteoporosis, connective tissue
disease, and osteoarthritis
bVariables excluded from the
final regression model based on
either not reaching 1% overall
prevalence or crude OR was not
statistically significant
cHRT was excluded from the
final regression model in order
to retain the full sample
(men and women)
Osteoporos Int (2010) 21:569–577 575associated with an increased risk of ON in the adjusted
model of all skeletal sites combined (Table 4) or in the
adjusted model for the hip subset (Table 5).
Discussion
From 1989 to 2003, in this study population, the observed
incidence of ON ranged from approximately 1.4–3.0/
100,000 within the combined GPRD/THIN dataset. The
reason for the increased incidence over time is not known
but could be due in part to the increasing use of more
advanced radiographic techniques, especially MRI, that are
more sensitive in detecting ON. Consistent with the
literature [1, 5], we found that the hip was the most
commonly diagnosed site for ON (75.9%) and that
corticosteroid use was associated with a 3-fold increased
risk for ON. Significant risk factors for ON at all skeletal
sites combined did not differ substantially from those for
ON of the hip. While we did not assess trauma specifically,
bone fracture in the prior 5 years was associated with a 5.8-
fold increased risk of ON at all skeletal sites both combined
and at the hip.
As observed in other studies, a history of connective
tissue disease or cancer were significant risk factors for ON.
This may be confounded by the frequent use of cortico-
steroids in these populations [4–6, 20]. In addition, overall
disease severity/morbidity may also contribute to a higher
rate of ON in these populations [1, 4]. There were two risk
factors that showed a risk reduction (70% with statin use
and 60% with diabetes mellitus); however, neither was
statistically significant and neither met the criteria for
inclusion in the multivariable model.
Our study population was 53% female. This contrasts
with previous findings that ON is more common in men
in the general population (with the exception of
systemic lupus erythematosus populations) [1]. In addi-
tion, the age of our study population ranged between 42
and 73 years (mean=57.6 years; median=59.0 years),
which is older than previously reported in the literature
[1, 21].
Although a history of osteoporosis in the prior 5 years
was a significant risk factor in this study, bisphosphonate
use was not. Only three cases had the jaw mentioned as the
site of ON, and none of these had been exposed to
bisphosphonates in the previous 2 years. In this study,
there were no cases of ON with intravenous bisphosphonate
use, which has been reported with ONJ in the treatment of
multiple myeloma and metastatic carcinoma in the literature
[16–19]. It should also be noted that the study period was
prior to the recent literature and recent awareness of ONJ.
Given that prior bone fracture was the strongest risk factor
observed in this study and that bisphosphonates are
indicated for the prevention and treatment of osteoporosis
that is often first identified after a fracture occurs,
confounding by indication may explain the observation of
bisphosphonate use and ON in the univariate analysis
(elevated crude OR).
There are several limitations to this study. As with the
use of any medical records database, misclassification bias
is possible. The case definition was developed to include all
available READ codes in order to minimize the likelihood
that true cases of ON were missed (i.e., sensitive) and that
cases were not falsely classified (i.e., specific). Some cases
of ON may not have been recorded or diagnosed; the
diagnosis of non-traumatic ON is difficult because the
disease is silent until pain presents [1]. In general, cases of
ONJ identified by dental professionals may not be
consistently recorded in the medical records databases.
Further, ONJ had no separate READ code during the study
period. To address this limitation, possible cases were
assessed from a review of the text fields for ON cases with
any mention of “jaw.” Another limitation is that prescrip-
tions written by specialists may not have been recorded by
the general practitioner. The study design was based on an a
priori selection of risk factors that have been previously
cited in the literature [1, 4–7, 15] with particular focus on
those that were highly correlated; therefore, this study may
have excluded other potentially important risk factors.
In conclusion, using data from the UK GPRD and THIN
databases, we found that significant predictors of ON at any
skeletal site included use of systemic corticosteroids in the
Type of bisphosphonate Cases (N=792) Controls (N=4660) Overall (N=5452)
Alendronate only 9 (26%) 9 (17%) 18 (20%)
Clodronate only 1 (3%) 0 (0%) 1 (1%)
Etidronate only 20 (57%) 42 (79%) 62 (70%)
Risedronate only 2 (6%) 1 (2%) 3 (3%)
Alendronate and risedronate 1 (3%) 0 (0%) 1 (1%)
Alendronate and etidronate 1 (3%) 1 (2%) 2 (2%)
Alendronate, etidronate, and risedronate 1 (3%) 0 (0%) 1 (1%)
Total number of cases/controls 35 53 88
Table 6 Types of bisphospho-
nates used by cases and controls
within the previous 2-year study
period
576 Osteoporos Int (2010) 21:569–577previous 2 years, hospitalization, referral or specialist visit,
bone fracture, any cancer, osteoporosis, connective tissue
disease, and osteoarthritis within the past 5 years.
Bisphosphonate use was not a significant predictor of ON.
This study aimed to provide a broader perspective on the
descriptive epidemiology of ON risk factors than previous
published studies. Studies utilizing more recent data may
further elucidate the understanding of key predictors of ON.
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